Strides Pharma Q2FY27 Revenue ₹14,297m, up 17% YoY

Strides Pharma Science Ltd reported a strong Q2FY27 performance with revenue reaching ₹14,297 million, a 17.1% increase year-on-year. The Ex-US markets showed significant growth of 31% YoY, contributing ₹6,963 million and surpassing the US business revenue for the first time. The US business grew 9% YoY to ₹6,855 million, with three new products launched. EBITDA rose 8.4% YoY to ₹2,509 million, crossing the ₹2,500 million mark in a quarter for the first time, despite increased input costs. Operational PAT increased by 11.5% YoY to ₹1,358 million. Net debt increased by ₹2,114 million in H1FY27 due to an elongated cash-to-cash cycle and higher inventory, with expectations to stabilize the Net Debt to EBITDA ratio by year-end. The company also announced the appointment of Mr. Biren Gabhawala as an Independent Director.